ArticleMedical oncology (Northwood, London, England)2013
Prognostic value of Th17 cells in acute leukemia.
Article in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Inflammation as a central driver in AML pathogenesis and therapy resistance.Science China. Life sciences · 2026Review
- Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity.Cancer cell · 2025Article
- Article
- Expression of interleukin-17 in oral tongue squamous cell carcinoma and its effect on biological behavior.Scientific reports · 2025Article
- Article
- Significance of Th17 and Treg in Treatment Efficacy and Outcome in Pediatric Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2023Article
- Divergent CD4Frontiers in immunology · 2023Article
- Elucidating the Heterogeneity of Serum Metabolism in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia by Raman Spectroscopy.ACS omega · 2022Article
- Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches.Proteomes · 2021Article
- Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment.Biomarker research · 2021Article
- Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer.The Journal of clinical investigation · 2020Article
- IL-17-Producing Cells in Tumor Immunity: Friends or Foes?Immune network · 2020Review
- Interleukin-17 Gene Polymorphism Is Protective Against the Susceptibility to Adult Acute Myeloid Leukaemia in Egypt: A Case-Control Study.Open access Macedonian journal of medical sciences · 2019Article
- Increased Th17 cells and IL-17A exist in patients with B cell acute lymphoblastic leukemia and promote proliferation and resistance to daunorubicin through activation of Akt signaling.Journal of translational medicine · 2016Article
- IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia.Journal of translational medicine · 2015Article
- The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review.Oncoimmunology · 2015Review
- Correlation between acute myeloid leukemia and IL-17A, IL-17F, and IL-23R gene polymorphism.International journal of clinical and experimental pathology · 2015Article
- IL-17F gene polymorphism is associated with susceptibility to acute myeloid leukemia.Journal of cancer research and clinical oncology · 2014Article
- Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia.Cancer science · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Th17 cells and their effector cytokines have emerged as important mediators in inflammatory and autoimmune diseases and serve as an ambitious field in current immunology research. Recent studies suggest a potential impact of Th17 cells on solid tumors but relatively little is known about their contribution in hematological malignancies. The current study was designed to investigate the possible involvement and clinical significance of circulating Th17 cells in acute leukemia. Flow cytometry was used to analyze percentages of Th17 cells in peripheral blood mononuclear cells from 93 acute leukemia patients (ALL, n = 30; AML, n = 63) and 40 healthy volunteers. Serum levels of IL-17 and IL-21 were measured using enzyme-linked immunosorbent assay. Circulating Th17 cells were increased in patients with acute leukemia (2.88 ± 0.65% and 2.90 ± 0.57% in ALL and AML patients, respectively) and were significantly higher than in healthy controls (1.10 ± 0.28%; P = 0.001). Furthermore, pretreatment Th17 cells were reduced significantly in patients who achieved complete remission after induction therapy (2.25 ± 0.44 % and 1.63 ± 0.27% in ALL and AML patients, respectively, P < 0.0001). Serum levels of IL-17 and IL-21 were significantly elevated in acute leukemia patients. Kaplan-Meier curves revealed a significantly longer overall survival in patients with high Th17 levels (P = 0.029 and P = 0.027 for ALL and AML, respectively). In the multivariate analysis, Th17 cells retained statistical significance for overall survival in patients with ALL (OR 0.331; P = 0.043) and AML (OR 0.489; P = 0.032). These results strongly suggest Th17 cells as a powerful new prognostic determinant which could serve as a potential therapeutic target to modulate anti-tumor response in acute leukemia patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.